# Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia

> **NCT04040621** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 4 (actual)

## Conditions studied

- Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia

## Interventions

- **DRUG:** Ceftazidime-avibactam

## Key facts

- **NCT ID:** NCT04040621
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-15
- **Primary completion:** 2021-04-09
- **Final completion:** 2021-05-07
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.
- **Last updated:** 2022-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04040621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04040621, "Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04040621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*